TWiV 1002: Clinical update with Dr. Daniel Griffin
Episode description
In his weekly clinical update, Dr. Griffin discusses completeness and spin of medRxiv preprints and associated published abstracts of COVID-19 randomized clinical trials, lessons learned from a COVID-19 dog screening pilot in California K-12 schools, SARS-CoV-2 reinfection and severity of the disease, effectiveness of COVID-19 bivalent vaccine, Molnupiravir and risk of post-acute sequelae of COVID-19, risk of new-onset long Covid following reinfection with SARS-CoV-2, low vitamin D levels associated with long COVID syndrome in COVID-19 survivors, and clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”.
Click arrow to play Download TWiV 1002 (27 MB .mp3, 44 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Completeness and spin of medRxiv preprint and published abstracts of COVID-19 randomized clinical trials (JAMA)
- Lessons learned from a COVID-19 dog screening pilot (JAMA)
- SARS-CoV-2 reinfection and severity of the disease (Viruses)
- Effectiveness of COVID-19 bivalent vaccine (medRxiv)
- Molnupiravir and risk of post-acute sequelae of COVID-19 (BMJ)
- Risk of new-onset long Covid following reinfection with SARS-CoV-2 (medRxiv)
- Low vitamin D levels are associated with Long COVID in COVID-19 survivors (JCEM)
- Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for treatment of Long-COVID19 (NIH)
- Contribute to our ASTMH fundraiser at PWB
- Letters read on TWiV 1002
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]